Orange Book product · Brand (NDA)
CANCIDAS
CASPOFUNGIN ACETATE
At a glance
Jan 26, 2001
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 26, 2001
25 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
CASPOFUNGIN ACETATE
Strength
70MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 021227
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2016CASPOFUNGIN ACETATEBrand (NDA)
NDA 206110 · FRESENIUS KABI USA
- 2025CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 216506 · HANGZHOU ZHONGMEI
- 2021CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 211263 · AREVA PHARMS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 209489 · CIPLA
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 205923 · XELLIA PHARMS APS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 200833 · HENGRUI PHARMA
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207092 · GLAND
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207650 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
